Skip to Content

BCR-ABL tyrosine kinase inhibitors

What are BCR-ABL tyrosine kinase inhibitors?

BCR-ABL tyrosine kinase inhibitors inhibit the enzyme BCR-ABL tyrosine kinase, which is important in the pathogenesis of chronic myelogenous leukemia (CML).

Chronic myelogenous leukemia occurs due a single genetic abnormality, known as the Philadelphia chromosome. During the translocation when the Philadelphia chromosome is created, a fusion gene called BCR-ABL gene is formed. The BCR-ABL gene encodes for the BCR-ABL tyrosine kinase. The BCR-ABL positive cells in chronic myelogenous leukemia have increased proliferation and resistance to cell death.

BCR-ABL tyrosine kinase inhibitors are used to treat chronic myelogenous leukemia.

List of BCR-ABL tyrosine kinase inhibitors:

Filter by:
Drug NameView by: Brand | Generic Reviews Avg. Ratings
imatinib systemic (Pro, More...)
35 reviews
dasatinib systemic (Pro, More...)
19 reviews
nilotinib systemic (Pro, More...)
26 reviews
bosutinib systemic (Pro, More...)
4 reviews
ponatinib systemic (Pro, More...)
2 reviews